![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 06, 2020 1:17:26 AM
3/4/20 Thero John F
Chief Executive Officer Sale 200,000 15.99 – 15.99 2,480,441 $3.2 M
2/28/20 Kennedy Joseph T
General Counsel Exercise of Options 3,612 -- – -- 193,507 $--
Thero John F
Chief Executive Officer Exercise of Options 13,472 -- – -- 2,680,441 $--
Ketchum Steven B
Officer Exercise of Options 3,056 -- – -- 516,012 $--
Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 3,056 -- – -- 83,927 $--
Berg Aaron D.
Officer Exercise of Options 3,056 -- – -- 188,905 $--
2/25/20 Thero John F
Chief Executive Officer Exercise of Options 229,030 -- – -- 2,672,271 $--
Kennedy Joseph T
General Counsel Exercise of Options 61,394 -- – -- 189,895 $--
Ketchum Steven B
Officer Exercise of Options 51,948 -- – -- 514,462 $--
Berg Aaron D.
Officer Exercise of Options 51,948 -- – -- 187,355 $--
Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 51,948 -- – -- 82,369 $--
1/31/20 Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 67,734 -- – -- 55,861 $--
Berg Aaron D.
Officer Exercise of Options 41,734 -- – -- 160,993 $--
Thero John F
Chief Executive Officer Exercise of Options 315,367 -- – -- 2,533,365 $--
Kennedy Joseph T
General Counsel Exercise of Options 74,734 -- – -- 160,825 $--
Ketchum Steven B
Officer Exercise of Options 67,734 -- – -- 488,100 $--
1/3/20 Zakrzewski Joseph S
Director Exercise of Options 300,000 3.40 – 3.40 84,547 $1.0 M
Zakrzewski Joseph S
Director Sale 300,000 20.94 – 20.94 84,547 $6.3 M
12/16/19 Kalb Michael Wayne ...
Chief Financial Officer Sale 25,000 23.05 – 25.66 21,552 $584.0 K
Berg Aaron D.
Officer Sale 43,253 25.46 – 25.46 133,806 $1.1 M
12/16/19 Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 25,000 2.19 – 2.19 21,552 $54.8 K
Berg Aaron D.
Officer Exercise of Options 43,253 12.60 – 12.60 133,806 $545.0 K
Zakrzewski Joseph S
Director Exercise of Options 100,000 9.00 – 9.00 84,547 $900.0 K
11/19/19 Thero John F
Chief Executive Officer Sale 274,454 22.65 – 22.65 2,342,285 $6.2 M
11/12/19 Ekman Lars G
Director Sale 38,600 19.35 – 19.35 -- $746.8 K
Ekman Lars G
Director Exercise of Options 38,600 14.40 – 14.40 -- $555.8 K
11/11/19 Thero John F
Chief Executive Officer Sale 475,546 17.05 – 17.88 2,616,739 $8.1 M
11/5/19 Ekman Lars G
Director Sale 6,400 18.00 – 18.00 -- $115.2 K
Ekman Lars G
Director Exercise of Options 6,400 14.40 – 14.40 -- $92.2 K
10/28/19 Thero John F
Chief Executive Officer Exercise of Options 11,601 2.50 – 2.50 3,092,285 $29.0 K
10/7/19 Thero John F
Chief Executive Officer Award of Options 1,265,250 0.000 – 0.000 3,080,684 $0.0
Kennedy Joseph T
General Counsel Award of Options 199,500 0.000 – 0.000 125,723 $0.0
Ketchum Steven B
Officer Award of Options 199,500 0.000 – 0.000 453,969 $0.0
Berg Aaron D.
Officer Award of Options 199,500 0.000 – 0.000 133,806 $0.0
9/3/19 Ekman Lars G
Director Sale 91,016 15.01 – 15.01 -- $1.4 M
Ekman Lars G
Director Exercise of Options 91,016 3.06 – 5.58 -- $320.3 K
8/21/19 Thero John F
Chief Executive Officer Exercise of Options 191,997 1.02 – 2.50 2,324,911 $300.0 K
Thero John F
Chief Executive Officer Exercise of Options 180,396 1.02 – 2.50 2,313,310 $271.0 K
7/11/19 Stack David M
Director Exercise of Options 51,991 2.19 – 2.50 -- $121.0 K
Stack David M
Director Sale 51,991 22.28 – 22.28 -- $1.2 M
7/2/19 Berg Aaron D.
Officer Exercise of Options 98,814 2.50 – 2.80 36,351 $255.8 K
Berg Aaron D.
Officer Sale 98,814 20.46 – 22.64 36,351 $2.1 M
7/1/19 Kennedy Joseph T
General Counsel Sale 54,186 19.52 – 19.52 31,260 $1.1 M
Kalb Michael Wayne ...
Chief Financial Officer Sale 50,000 19.67 – 19.67 20,840 $983.3 K
Kennedy Joseph T
General Counsel Exercise of Options 27,244 1.40 – 3.80 31,260 $70.0 K
Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 50,000 2.19 – 2.19 20,840 $109.5 K
6/28/19 Thero John F
Chief Executive Officer Exercise of Options 37,500 -- – -- 2,132,914 $--
Kennedy Joseph T
General Counsel Exercise of Options 53,437 -- – -- 58,202 $--
6/24/19 Berg Aaron D.
Officer Exercise of Options 100,000 2.50 – 2.50 36,351 $250.0 K
Berg Aaron D.
Officer Sale 113,195 18.59 – 18.59 36,351 $2.1 M
6/18/19 Zakrzewski Joseph S
Director Sale 100,000 19.02 – 19.02 84,547 $1.9 M
Zakrzewski Joseph S
Director Exercise of Options 100,000 3.40 – 3.40 84,547 $340.0 K
5/31/19 Kennedy Joseph T
General Counsel Sale 27,229 17.92 – 17.92 31,260 $488.1 K
Kennedy Joseph T
General Counsel Exercise of Options 27,229 1.40 – 3.80 31,260 $69.9 K
5/29/19 Stack David M
Director Exercise of Options 33,799 3.21 – 3.21 -- $108.5 K
Stack David M
Director Sale 33,799 18.45 – 18.45 -- $623.5 K
5/17/19 Stack David M
Director Sale 13,174 18.00 – 18.00 -- $237.1 K
Stack David M
Director Exercise of Options 13,174 3.21 – 3.21 -- $42.3 K
5/1/19 Berg Aaron D.
Officer Exercise of Options 26,000 -- – -- 49,546 $--
4/30/19 Kennedy Joseph T
General Counsel Exercise of Options 27,230 1.40 – 3.80 31,260 $69.9 K
4/30/19 Ketchum Steven B
Officer Sale 9,541 18.67 – 18.67 354,492 $178.1 K
4/1/19 Ketchum Steven B
Officer Sale 9,542 20.05 – 20.78 354,492 $191.4 K
Kennedy Joseph T
General Counsel Sale 54,172 20.03 – 20.80 31,260 $1.1 M
Ketchum Steven B
Officer Exercise of Options 9,542 1.40 – 2.95 354,492 $22.2 K
InvestorsHub NewsWire
Altitude International Announces Name Change and Corporate Expansion • ALTD • Apr 3, 2020 4:10 PM
Enertopia Announces Maiden NI 43-101 Resource Estimate • ENRT • Apr 2, 2020 1:30 PM
REDHAWK ANNOUNCES RECENT ESCALATION IN NEW ORDERS OF MEDICAL DEVICES & SUPPLIES • SNDD • Apr 2, 2020 1:30 PM
Bantec Inc's Subsidiary Howco Deemed an Essential DOD Business in the Fight Against the Covid-19 Threat • BANT • Apr 2, 2020 9:40 AM
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM